Latest Foresite Capital Management IV, LLC Stock Portfolio
Foresite Capital Management IV, LLC Performance:
2025 Q2: 6.05%YTD: 0.73%2024: -21.32%
Performance for 2025 Q2 is 6.05%, and YTD is 0.73%, and 2024 is -21.32%.
About Foresite Capital Management IV, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Foresite Capital Management IV, LLC reported an equity portfolio of $123.8 Millions as of 30 Jun, 2025.
The top stock holdings of Foresite Capital Management IV, LLC are PHVS, , LYEL. The fund has invested 62.7% of it's portfolio in PHARVARIS N.V. and 20.9% of portfolio in MAZE THERAPEUTICS INC.
The fund managers got completely rid off LYELL IMMUNOPHARMA, INC. (LYEL) stocks. They significantly reduced their stock positions in KURA ONCOLOGY, INC. (KURA). Foresite Capital Management IV, LLC opened new stock positions in LYELL IMMUNOPHARMA, INC. (LYEL) and XENON PHARMACEUTICALS INC (XENE).
The top stock holdings of Foresite Capital Management IV, LLC are PHVS, , LYEL. The fund has invested 62.7% of it's portfolio in PHARVARIS N.V. and 20.9% of portfolio in MAZE THERAPEUTICS INC.
The fund managers got completely rid off LYELL IMMUNOPHARMA, INC. (LYEL) stocks. They significantly reduced their stock positions in KURA ONCOLOGY, INC. (KURA). Foresite Capital Management IV, LLC opened new stock positions in LYELL IMMUNOPHARMA, INC. (LYEL) and XENON PHARMACEUTICALS INC (XENE).
Foresite Capital Management IV, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Foresite Capital Management IV, LLC made a return of 6.05% in the last quarter. In trailing 12 months, it's portfolio return was -22.24%.
New Buys
| Ticker | $ Bought |
|---|---|
| lyell immunopharma, inc. | 7,075,530 |
| xenon pharmaceuticals inc | 5,008,000 |
New stocks bought by Foresite Capital Management IV, LLC
Additions
Reductions
| Ticker | % Reduced |
|---|---|
| kura oncology, inc. | -26.53 |
Foresite Capital Management IV, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| lyell immunopharma, inc. | -8,612,300 |
Foresite Capital Management IV, LLC got rid off the above stocks
Sector Distribution
Foresite Capital Management IV, LLC has about 83.6% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 83.6 |
| Healthcare | 16.4 |
Market Cap. Distribution
Foresite Capital Management IV, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 83.6 |
| SMALL-CAP | 12.3 |
| MID-CAP | 4 |
Stocks belong to which Index?
About 12.3% of the stocks held by Foresite Capital Management IV, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 87.7 |
| RUSSELL 2000 | 12.3 |
Foresite Capital Management IV, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Foresite Capital Management IV, LLC
Foresite Capital Management IV, LLC has 6 stocks in it's portfolio. KURA proved to be the most loss making stock for the portfolio. LYEL was the most profitable stock for Foresite Capital Management IV, LLC last quarter.
Last Reported on: 12 Aug, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| PHVS | pharvaris n.v. | 62.70 | 4,410,580 | 77,626,200 | unchanged | 0.00 | ||
Historical Trend of PHARVARIS N.V. Position Held By Foresite Capital Management IV, LLCWhat % of Portfolio is PHVS?:Number of PHVS shares held:Change in No. of Shares Held: | ||||||||
| maze therapeutics inc | 20.93 | 2,111,920 | 25,913,200 | unchanged | 0.00 | |||
| LYEL | lyell immunopharma, inc. | 5.72 | 800,399 | 7,075,530 | new | |||
| XENE | xenon pharmaceuticals inc | 4.04 | 160,000 | 5,008,000 | new | |||
| KURA | kura oncology, inc. | 3.81 | 816,882 | 4,713,410 | reduced | -26.53 | ||
| RLAY | relay therapeutics inc. | 2.80 | 1,000,000 | 3,460,000 | unchanged | 0.00 | ||
| LYEL | lyell immunopharma, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
